← Leaderboards
Francis S Markland
Pivotal Biosciences, Inc.
$828,127
Attributed
$828,127
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$828,127 · 4
By mechanism
R41$828,127 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Angiogenesis Inhibitors”
- Walter John Curran · Thomas Jefferson University$26,641,549
- David Heimbrook · Leidos Biomedical Research, Inc.$24,469,358
- David R Harder · Medical College Of Wisconsin$16,163,720
- Elizabeth Marion Jaffee · Johns Hopkins University$12,679,276
- Garrett M Brodeur · Children'S Hospital Of Philadelphia$12,442,187
- Erwin G Van Meir · University Of Alabama At Birmingham$11,726,130
Research focus
Angiogenesis InhibitorsLiposomesAngiogenesisCyclic GmpCollectionContortrostatinClinical ApplicationAthymic MouseChemotherapeutic AgentChemotherapyClinical Trials, Phase IiAnticancer ActivityCombined Modality TherapyConditionAffinityCancer CellCell LineBaseCharacteristicsBiologicalBiotherapeutic AgentAnimalsClinical TrialsClinical Data
Grant awards (4)
Development of a combination therapy for the treatment of prostate cancer$249,949
R41 · FY2007 · CA · contact PI
Liposomal Disintegrin: Novel and Effective Antitumor Agent Phase I$248,564
R41 · FY2007 · CA · contact PI
Antiidiotype mAb:an Antiangiogenic /Antimetastatic Agent$122,433
R41 · FY2002 · CA
TREATMENT OF OVARIAN CANCER WITH CONTORTROSTATIN$207,181
R41 · FY2001 · CA